The Rise of Psilocybin Use in the United States: A Multisource Observational Study
Annals of Internal Medicine April 21, 2025 Karilynn Rockhill, Joshua C. Black, Michael S. Ladka et al. 29 citations
No Summary
R. Cameron Wolf
4 papers in the library · 49 citations · publishing 2024-2026
Papers
Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study
Journal of Psychopharmacology June 18, 2024 Kim Hoffman, Alissa Bazinet, Kellie Pertl et al. 14 citations
Experts with extensive experience facilitating psilocybin experiences, including in ceremonial settings, indigenous practices, and clinical trials, developed a set of core measures to monitor the safety, quality, and outcomes of supervised psilocybin services. Through a three-phase e-Delphi process with 36 experts, 55 candidate measures were identified and then prioritized to a core set of 11 process measures (e.g., preparatory hours with client, documentation of touch/sexual boundaries), 11 outcome measures (e.g., adverse events, well-being), and 17 structure measures (e.g., facilitator training in trauma informed care). The findings suggest that service providers and policy makers should consider standardizing these measures for community-based psilocybin services.
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.
Am J Psychiatry January 1, 2025 Aaron S. Wolfgang, Vetisha L. McClair, Paula P. Schnurr et al. 6 citations
The Veterans Health Administration (VHA) is exploring the integration of psychedelic-assisted therapy as a potential treatment for veterans with mental health conditions, particularly PTSD. The text outlines the need for careful research and implementation strategies within the VHA system, emphasizing safe integration, care pathways, and the development of clinical protocols. It highlights the importance of addressing regulatory, ethical, and logistical challenges to ensure veteran well-being and recovery. The work suggests that psychedelic-assisted therapies could offer innovative treatment options, but rigorous study and structured implementation are necessary before widespread adoption.
Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study
Neuroethics May 13, 2026 Christina Chwyl, Alissa Bazinet, Adrianne R. Wilson-Poe et al.
Informed consent in psychedelic-assisted services is ethically complex and lacks standardization. Expert recommendations from 36 participants (71% white, 53% female, average 15.2 years of experience in clinical trial, underground, or ceremonial settings) emphasized that consent should be an ongoing process built on a strong therapeutic relationship and client empowerment. Comprehensive disclosure of risks and benefits is needed, including long-term psychological and social changes and the possibility of disappointing experiences. Detailed consent around touch and boundaries is crucial, with explicit boundary-setting before administration and attention to non-verbal cues. Provider training should cultivate deep respect for client agency and experiential learning of relational and boundary skills.